Novartis plans to invest in manufacturing facility in Switzerland

Novartis CEO Joseph Jimenez said the investment is strengthening the importance of Stein as Manufacturing Center of Excellence for sterile and solid dosage forms and will play a key role in the company’s global production network.

"It also strengthens our presence in Switzerland, which remains a center of key importance for Novartis," Jimenez added.

The new set-up, which will serve approximately 150 markets globally, will allow Novartis to adapt its production capacity depending on the market demand.

The Stein site in Canton Aargau produces over 4.1bn tablets, capsules, ampoules, prefilled syringes, vials and transdermal therapeutic systems each year.